Background: Peptidylarginine Deiminase 4 (PAD4) may generate epitopes targeted by anti-citrullinated protein antibodies in rheumatoid arthritis (RA). A subset of RA patients has serum autoantibodies to human recombinant PAD4 (hPAD4). Here, we assessed whether anti-hPAD4 status in RA predicted disease outcome after anti-TNF-α therapy.
Methods: We analyzed RA sera obtained at baseline (n=40) and after one year on anti-TNF-α therapy (n=33) for anti-hPAD4 IgG. Association analyses between baseline anti-hPAD status and disease progression were performed.
Results: We found that 17 of 40 patients (42.5%) were serum anti-hPAD4 positive at baseline, and the anti-hPAD4 IgG levels were stable over one year on anti-TNF-α therapy. At baseline, there were indications that the anti-hPAD4 positive patients had more severe disease than the negative patients. After one year on anti-TNF-α therapy, the anti-hPAD4 positive patients displayed persistently elevated DAS28 score and increased progression in the vdHSharp erosion score. Accordingly, more anti-hPAD4 positive than negative patients presented an increase in vdHSharp erosion scores >0 over one year.
Conclusion: Anti-hPAD4 IgG can be detected in a subset of RA sera and the levels are stable after initiation of anti-TNF-α therapy. Serum anti-hPAD4 may predict persistent disease activity and radiographic progression in RA patients receiving anti-TNF-α therapy.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.